Because the average concentration of shed MSLN in the blood is ~6 nM in a tumor of ~300 mm3, 89Zr-amatuximab (1.75 nM) would be mostly bound to shed MSLN in blood during a 48 h period and this complex sequestered into liver and spleen. The gene discussed is MSLN; the disease is neoplasm.